NovoCure Ltd
NVCRUS売上高
$655M
百万USD
営業利益
$-154M
百万USD
純利益
$-136M
百万USD
ROE
-40.0%
最新FY
EPS
$-1.22
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $135M | $-4M | $-0.04 |
| FY2021 | Q2 | $134M | $-15M | $-0.14 |
| FY2021 | Q3 | $134M | $-13M | $-0.13 |
| FY2021 | FY | $535M | $-58M | $-0.56 |
| FY2022 | Q1 | $138M | $-5M | $-0.04 |
| FY2022 | Q2 | $141M | $-24M | $-0.23 |
| FY2022 | Q3 | $131M | $-27M | $-0.25 |
| FY2022 | FY | $538M | $-93M | $-0.88 |
| FY2023 | Q1 | $122M | $-53M | $-0.50 |
| FY2023 | Q2 | $126M | $-57M | $-0.54 |
| FY2023 | Q3 | $127M | $-49M | $-0.46 |
| FY2023 | FY | $509M | $-207M | $-1.95 |
| FY2024 | Q1 | $139M | $-39M | $-0.36 |
| FY2024 | Q2 | $150M | $-33M | $-0.31 |
| FY2024 | Q3 | $155M | $-31M | $-0.28 |
| FY2024 | FY | $605M | $-169M | $-1.56 |
| FY2025 | Q1 | $155M | $-34M | $-0.31 |
| FY2025 | Q2 | $159M | $-40M | $-0.36 |
| FY2025 | Q3 | $167M | $-37M | $-0.33 |
| FY2025 | FY | $655M | $-136M | $-1.22 |
| FY2026 | Q1 | $174M | $-71M | $-0.62 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $248M | $351M | $494M | $535M | $538M | $509M | $605M | $655M |
| 営業利益 | $-115M | $-39M | $-34M | $-1M | $30M | $-44M | $-90M | $-233M | $-170M | $-154M |
| 純利益 | $-132M | $-62M | $-64M | $-7M | $20M | $-58M | $-93M | $-207M | $-169M | $-136M |
| 総資産 | $282M | $265M | $340M | $479M | $1.1B | $1.1B | $1.2B | $1.1B | $1.2B | $804M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $142M | $114M | $112M | $218M | $477M | $410M | $441M | $362M | $360M | $340M |
| 営業CF | - | - | $-2M | $27M | $99M | $83M | $31M | $-73M | $-26M | $-49M |
| EPS | - | - | - | - | $0.18 | $-0.56 | $-0.88 | $-1.95 | $-1.56 | $-1.22 |
| BPS | $1.63 | $1.26 | $1.18 | $2.19 | $4.65 | $3.93 | $4.18 | $3.38 | $3.28 | $2.99 |
| ROE | -92.6% | -54.3% | -56.6% | -3.3% | 4.2% | -14.2% | -21.0% | -57.1% | -46.8% | -40.0% |